Clinical trials: Esrd
End Stage Renal Disease, ESRD
Early Feasibility Study to Evaluate the Safety and Efficacy of PAK HD in ESRD Patients
The purpose of this study is to demonstrate the safety of dialysate regeneration of the PAK HD sorbent cartridge and therapy efficacy of the PAK HD sorbent therapy compared with conventional hemodialysis.
- Trial name
- NCT06433193
- Testing
- PAK HD Sorbent Therapy
- Where
- Singapore
- Volunteers
- 3 people
- Sponsor
- Nextkidney S.A.
Renal Impairment
PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients
This is a clinical study to investigate the pharmacokinetics/pharmacodynamics and tolerability of DA-1229(Evogliptin) tabletin renal impaired patients.
- Trial name
- NCT02214693
- Testing
- DA-1229
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
End Stage Renal Disease
Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
The InterGraft™ Venous Anastomotic Connector provides an endovascular, minimally invasive means for attachment of an arteriovenous graft to a vein in the upper extremity.
- Trial name
- NCT02532621
- Testing
- Venous InterGraft Connector, sutured arterial anastomosis of an implanted vascular graft for hemodialysis, hemodialysis
- Where
- 10 sites in United States
- Volunteers
- 158 people
- Sponsor
- Phraxis, Inc.
Pulmonary Disease, Chronic Obstructive
Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment
This study will assess the safety and pharmacokinetics of inhaled GSK573719 and GSK573719/vilanterol combination in healthy subjects and in subjects with severe renal impairment.
- Trial name
- NCT01571999
- Testing
- Inhaled GSK573719, Inhaled GSK573719/vilanterol
- Where
- 2 sites in Czechia, Hungary
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Renal Insufficiency, Chronic
Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
- Trial name
- NCT00048438
- Testing
- paricalcitol
- Where
- 18 sites in United States, Poland
- Volunteers
- 68 people
- Sponsor
- Abbott
Arterio-Venous Fistula, Kidney Failure, Chronic
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
This is a prospective single arm study enrolling patients who are scheduled for creation of a new Brachiocephalic or Radiocephalic AV fistula.
- Conditions
- Arterio-Venous Fistula, Kidney Failure, Chronic, Kidney Diseases, Renal Failure Chronic
- Trial name
- VALUE (NCT03246984)
- Testing
- VasQ
- Where
- 11 sites in France, Germany and 2 more
- Volunteers
- 80 people
- Sponsor
- Laminate Medical Technologies
Renal Impairment
Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543
This is an open-label, single-dose, sequentially designed, single-period study to determine the effect of moderate renal impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a…
- Trial name
- NCT05468749
- Testing
- CTP-543
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Concert Pharmaceuticals
Anemia in Chronic Kidney Disease
An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD
FMX-8 is a new type of drug being tested for the treatment of anemia in chronic illnesses.
- Trial name
- NCT02228655
- Testing
- FMX-8
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- FerruMax Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
- Trial name
- NCT04515849
- Testing
- Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms
- Where
- 83 sites in Australia, Canada and 6 more
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Renal Insufficiency, Healthy
A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.
- Trial name
- NCT03302091
- Testing
- BI 1467335
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease, CKD
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who…
- Conditions
- Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
- Trial name
- ARTEMIS (NCT05746559)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 18 more
- Volunteers
- 555 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Kidney Diseases
everlinQ Endovascular Access Systems Enhancements (EASE-2) Study
Prospective, single-center study to evaluate the everlinQ endoAVF System when used to create an endoAVF in hemodialysis patients.
- Trial name
- NCT03708562
- Testing
- everlinQ endoAVF System
- Where
- Paraguay
- Volunteers
- 24 people
- Sponsor
- C. R. Bard
End Stage Renal Disease
A Safety Study of Pentoxifylline for the Treatment of Anemia
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease.
- Trial name
- NCT01102218
- Testing
- Erythropoietin, Pentoxifylline
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- Fresenius Medical Care North America
Chronic Renal Failure, Chronic Kidney Disease
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
The purpose of this study was to evaluate the long term safety and tolerability of peginesatide for the maintenance of hemoglobin in participants with chronic kidney disease (CKD) who had received at least 24 weeks of…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- NCT00372489
- Testing
- peginesatide
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Affymax
Chronic Kidney Disease
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease.
- Trial name
- NCT03594110
- Testing
- Empagliflozin
- Where
- 240 sites in United States, Canada and 6 more
- Volunteers
- 6,609 people
- Sponsor
- Boehringer Ingelheim
Acute Kidney Injury
A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy
The purpose of this study is to assess the safety and tolerability of the investigational product, SBI-101, in subjects with Acute Kidney Injury (AKI) who require continuous renal replacement therapy.
- Trial name
- NCT03015623
- Testing
- SBI-101
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sentien Biotechnologies, Inc.
End Stage Kidney Disease
The Vascutek Rapidax™ II Post Market Surveillance Registry
Multicentre, prospective, observational post-market registry. To monitor and collect data on the post-market clinical safety and performance of the Vascutek Rapidax II Vascular Access Graft.
- Trial name
- NCT01977508
- Testing
- ePTFE vascular access grafts
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Vascutek Ltd.
End Stage Renal Disease, Inflammation
Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers
The study is a prospective cohort trial utilizing sequential laboratory results from excess serum obtained from hemodialysis patients (acting as their own controls).
- Trial name
- NCT00440908
- Where
- 2 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Fresenius Medical Care North America
Anemia, Kidney Failure, Chronic
Dynepo Long-Term Safety Study
To assess the incidence rate of Treatment Emergent Adverse Events (TEAEs) over 2 years in patients treated with Dynepo.
- Trial name
- NCT00514813
- Testing
- Dynepo
- Where
- Belgium
- Volunteers
- 152 people
- Sponsor
- Shire
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.